drugset / Trial / NCT02161653

Metadoxine as a Therapy for Severe Alcoholic Hepatitis

NCT02161653

Phase 4 Completed 135 enrolled Hospital General de Mexico
RandomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study is to determine whether metadoxine is effective for improve survival and reduced oxidative stress in patients with severe alcoholic hepatitis.

Timeline

Start
2010-04
Primary completion
2014-09
Completion
2014-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Metadoxine Unknown 500 mg Oral
Subject Pentoxifylline Small molecule 400 mg Oral
Subject Prednisone Other / unclassified 40 mg Oral

Indications